Investigational drug · Phase 3
LAM561
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Primary Glioblastoma, Glioblastoma Multiforme, High-grade Glioma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "LAM561"
First trial start
2019
Dec 1, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LAM561", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Glioblastoma
- Glioblastoma Multiforme
- High-grade Glioma
- Solid Tumor, Unspecified, Child
Approved drugs for the same conditions: Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "LAM561" as an intervention, largest first.
- LAM561 With RT and TMZ for Adults With GlioblastomaPivotal-lookingActive, not recruiting
Laminar PharmaceuticalsIndustry
NCT04250922 · 144 participants · Start Dec 1, 2019 · Primary completion Jan 15, 2026
Drug: LAM561; TMZ · For: Primary Glioblastoma; Glioblastoma Multiforme
Sites: Angers, France; Rennes, France; Toulouse, France · 22 sites in all
Laminar PharmaceuticalsIndustry
NCT01792310 · 54 participants · Start May 2013 · Primary completion Sep 2016
Drug: LAM561 · For: Glioma; Other Solid Tumours
Sites: Barcelona, Spain; Bilbao, Spain; San Sebastián, Spain · 5 sites in all
- Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid TumorsRecruiting
Laminar PharmaceuticalsIndustry
NCT04299191 · 28 participants (planned) · Start Sep 1, 2020 · Primary completion Oct 2026
Drug: LAM561 · For: High-grade Glioma; Solid Tumor, Unspecified, Child
Sites: Little Rock, Arkansas; Miami, Florida; Edison, New Jersey
Laminar PharmaceuticalsIndustry
NCT03867123 · 18 participants · Start Dec 4, 2018 · Primary completion Jul 1, 2020
Drug: LAM561; TMZ · For: Glioblastoma (GBM)
Sites: Badalona, Spain; Girona, Spain; L'Hospitalet de Llobregat, Spain
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.